B+
Bull case
20%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
IBIO
iBioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+71.6
Score
AI commentary
Primary-source earnings evidence is operationally constructive because of IBIO-600 clinical progress, pipeline expansion, and reported runway into fiscal 2028. However, the company is low coverage, pre-revenue, and highly event-driven. Consensus surprise, analyst revisions, options, short-interest, social coverage, and a trustworthy attribution of the post-release price reaction are unavailable; missing data is not positive evidence. Overall interpretation remains cautious and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-09-09
Open post-earnings memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-28eventFY2026 earnings and clinical-stage transitionMedium impact
The FY2026 release reported $0.1 million of revenue, $19.6 million of R&D expense, approximately $88 million of cash and investments, and cash runway into fiscal 2028. IBIO-600 completed dosing in 31 of 32 planned participants in the single-ascending-dose Phase 1 portion, with no safety findings precluding escalation [#SEC-8K-2026-08-28]. No reliable consensus surprise or analyst revision data was available.
2026-11-30eventIBIO-600 multiple-ascending-dose Phase 1 escalationHigh impact
iBio stated it was preparing the multiple-ascending-dose portion of IBIO-600's Phase 1 trial after completing the single-ascending-dose portion without safety findings that precluded escalation [#SEC-8K-2026-08-28].
2027-09-01catalystIBIO-610 IND-enabling developmentHigh impact
IBIO-610 advanced into IND-enabling studies following early nonclinical data in rodents and obese non-human primates. The evidence remains preclinical and includes small, non-statistically powered studies [#SEC-8K-2026-08-28] [#SEC-8K-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology